Global Nanocarrier-Based Vaccine Market Research Report 2023
Nanocarrier-based adjuvants and delivery vehicles such as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles, colloidally stable nanoparticles, proteosomes; and pattern recognition receptors covering c-type lectin receptors and toll-like receptors.
According to QYResearch’s new survey, global Nanocarrier-Based Vaccine market is projected to reach US$ 806.5 million in 2029, increasing from US$ 436 million in 2022, with the CAGR of 9.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nanocarrier-Based Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Nanocarrier-Based Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Nanocarrier-Based Vaccine market is projected to reach US$ 806.5 million in 2029, increasing from US$ 436 million in 2022, with the CAGR of 9.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nanocarrier-Based Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Nanocarrier-Based Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Emergent BioSolutions
- Sanofi
- GlaxoSmithKline Biologicals
- Merck
- Pfizer
- Novartis
- Moderna
- Adjuvants
- Delivery Systems
- Hospital
- Clinic
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Adjuvants
1.2.3 Delivery Systems
1.3 Market by Application
1.3.1 Global Nanocarrier-Based Vaccine Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Nanocarrier-Based Vaccine Market Perspective (2018-2029)
2.2 Nanocarrier-Based Vaccine Growth Trends by Region
2.2.1 Global Nanocarrier-Based Vaccine Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nanocarrier-Based Vaccine Historic Market Size by Region (2018-2023)
2.2.3 Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029)
2.3 Nanocarrier-Based Vaccine Market Dynamics
2.3.1 Nanocarrier-Based Vaccine Industry Trends
2.3.2 Nanocarrier-Based Vaccine Market Drivers
2.3.3 Nanocarrier-Based Vaccine Market Challenges
2.3.4 Nanocarrier-Based Vaccine Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Nanocarrier-Based Vaccine Players by Revenue
3.1.1 Global Top Nanocarrier-Based Vaccine Players by Revenue (2018-2023)
3.1.2 Global Nanocarrier-Based Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global Nanocarrier-Based Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nanocarrier-Based Vaccine Revenue
3.4 Global Nanocarrier-Based Vaccine Market Concentration Ratio
3.4.1 Global Nanocarrier-Based Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nanocarrier-Based Vaccine Revenue in 2022
3.5 Nanocarrier-Based Vaccine Key Players Head office and Area Served
3.6 Key Players Nanocarrier-Based Vaccine Product Solution and Service
3.7 Date of Enter into Nanocarrier-Based Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NANOCARRIER-BASED VACCINE BREAKDOWN DATA BY TYPE
4.1 Global Nanocarrier-Based Vaccine Historic Market Size by Type (2018-2023)
4.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029)
5 NANOCARRIER-BASED VACCINE BREAKDOWN DATA BY APPLICATION
5.1 Global Nanocarrier-Based Vaccine Historic Market Size by Application (2018-2023)
5.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Nanocarrier-Based Vaccine Market Size (2018-2029)
6.2 North America Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
6.4 North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Nanocarrier-Based Vaccine Market Size (2018-2029)
7.2 Europe Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
7.4 Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Nanocarrier-Based Vaccine Market Size (2018-2029)
8.2 Asia-Pacific Nanocarrier-Based Vaccine Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2018-2023)
8.4 Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Nanocarrier-Based Vaccine Market Size (2018-2029)
9.2 Latin America Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
9.4 Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Nanocarrier-Based Vaccine Market Size (2018-2029)
10.2 Middle East & Africa Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
10.4 Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Emergent BioSolutions
11.1.1 Emergent BioSolutions Company Detail
11.1.2 Emergent BioSolutions Business Overview
11.1.3 Emergent BioSolutions Nanocarrier-Based Vaccine Introduction
11.1.4 Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.1.5 Emergent BioSolutions Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Nanocarrier-Based Vaccine Introduction
11.2.4 Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 GlaxoSmithKline Biologicals
11.3.1 GlaxoSmithKline Biologicals Company Detail
11.3.2 GlaxoSmithKline Biologicals Business Overview
11.3.3 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Introduction
11.3.4 GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.3.5 GlaxoSmithKline Biologicals Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Nanocarrier-Based Vaccine Introduction
11.4.4 Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Nanocarrier-Based Vaccine Introduction
11.5.4 Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Nanocarrier-Based Vaccine Introduction
11.6.4 Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Moderna
11.7.1 Moderna Company Detail
11.7.2 Moderna Business Overview
11.7.3 Moderna Nanocarrier-Based Vaccine Introduction
11.7.4 Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.7.5 Moderna Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Adjuvants
1.2.3 Delivery Systems
1.3 Market by Application
1.3.1 Global Nanocarrier-Based Vaccine Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Nanocarrier-Based Vaccine Market Perspective (2018-2029)
2.2 Nanocarrier-Based Vaccine Growth Trends by Region
2.2.1 Global Nanocarrier-Based Vaccine Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nanocarrier-Based Vaccine Historic Market Size by Region (2018-2023)
2.2.3 Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029)
2.3 Nanocarrier-Based Vaccine Market Dynamics
2.3.1 Nanocarrier-Based Vaccine Industry Trends
2.3.2 Nanocarrier-Based Vaccine Market Drivers
2.3.3 Nanocarrier-Based Vaccine Market Challenges
2.3.4 Nanocarrier-Based Vaccine Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Nanocarrier-Based Vaccine Players by Revenue
3.1.1 Global Top Nanocarrier-Based Vaccine Players by Revenue (2018-2023)
3.1.2 Global Nanocarrier-Based Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global Nanocarrier-Based Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nanocarrier-Based Vaccine Revenue
3.4 Global Nanocarrier-Based Vaccine Market Concentration Ratio
3.4.1 Global Nanocarrier-Based Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nanocarrier-Based Vaccine Revenue in 2022
3.5 Nanocarrier-Based Vaccine Key Players Head office and Area Served
3.6 Key Players Nanocarrier-Based Vaccine Product Solution and Service
3.7 Date of Enter into Nanocarrier-Based Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NANOCARRIER-BASED VACCINE BREAKDOWN DATA BY TYPE
4.1 Global Nanocarrier-Based Vaccine Historic Market Size by Type (2018-2023)
4.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029)
5 NANOCARRIER-BASED VACCINE BREAKDOWN DATA BY APPLICATION
5.1 Global Nanocarrier-Based Vaccine Historic Market Size by Application (2018-2023)
5.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Nanocarrier-Based Vaccine Market Size (2018-2029)
6.2 North America Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
6.4 North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Nanocarrier-Based Vaccine Market Size (2018-2029)
7.2 Europe Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
7.4 Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Nanocarrier-Based Vaccine Market Size (2018-2029)
8.2 Asia-Pacific Nanocarrier-Based Vaccine Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2018-2023)
8.4 Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Nanocarrier-Based Vaccine Market Size (2018-2029)
9.2 Latin America Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
9.4 Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Nanocarrier-Based Vaccine Market Size (2018-2029)
10.2 Middle East & Africa Nanocarrier-Based Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
10.4 Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Emergent BioSolutions
11.1.1 Emergent BioSolutions Company Detail
11.1.2 Emergent BioSolutions Business Overview
11.1.3 Emergent BioSolutions Nanocarrier-Based Vaccine Introduction
11.1.4 Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.1.5 Emergent BioSolutions Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Nanocarrier-Based Vaccine Introduction
11.2.4 Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 GlaxoSmithKline Biologicals
11.3.1 GlaxoSmithKline Biologicals Company Detail
11.3.2 GlaxoSmithKline Biologicals Business Overview
11.3.3 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Introduction
11.3.4 GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.3.5 GlaxoSmithKline Biologicals Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Nanocarrier-Based Vaccine Introduction
11.4.4 Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Nanocarrier-Based Vaccine Introduction
11.5.4 Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Nanocarrier-Based Vaccine Introduction
11.6.4 Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Moderna
11.7.1 Moderna Company Detail
11.7.2 Moderna Business Overview
11.7.3 Moderna Nanocarrier-Based Vaccine Introduction
11.7.4 Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
11.7.5 Moderna Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Adjuvants
Table 3. Key Players of Delivery Systems
Table 4. Global Nanocarrier-Based Vaccine Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Nanocarrier-Based Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Nanocarrier-Based Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Nanocarrier-Based Vaccine Market Share by Region (2018-2023)
Table 8. Global Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Nanocarrier-Based Vaccine Market Share by Region (2024-2029)
Table 10. Nanocarrier-Based Vaccine Market Trends
Table 11. Nanocarrier-Based Vaccine Market Drivers
Table 12. Nanocarrier-Based Vaccine Market Challenges
Table 13. Nanocarrier-Based Vaccine Market Restraints
Table 14. Global Nanocarrier-Based Vaccine Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Nanocarrier-Based Vaccine Market Share by Players (2018-2023)
Table 16. Global Top Nanocarrier-Based Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Table 17. Ranking of Global Top Nanocarrier-Based Vaccine Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Nanocarrier-Based Vaccine Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Nanocarrier-Based Vaccine Product Solution and Service
Table 21. Date of Enter into Nanocarrier-Based Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2018-2023)
Table 25. Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2024-2029)
Table 27. Global Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Nanocarrier-Based Vaccine Revenue Market Share by Application (2018-2023)
Table 29. Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Nanocarrier-Based Vaccine Revenue Market Share by Application (2024-2029)
Table 31. North America Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Nanocarrier-Based Vaccine Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 46. Emergent BioSolutions Company Detail
Table 47. Emergent BioSolutions Business Overview
Table 48. Emergent BioSolutions Nanocarrier-Based Vaccine Product
Table 49. Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 50. Emergent BioSolutions Recent Development
Table 51. Sanofi Company Detail
Table 52. Sanofi Business Overview
Table 53. Sanofi Nanocarrier-Based Vaccine Product
Table 54. Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 55. Sanofi Recent Development
Table 56. GlaxoSmithKline Biologicals Company Detail
Table 57. GlaxoSmithKline Biologicals Business Overview
Table 58. GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Product
Table 59. GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 60. GlaxoSmithKline Biologicals Recent Development
Table 61. Merck Company Detail
Table 62. Merck Business Overview
Table 63. Merck Nanocarrier-Based Vaccine Product
Table 64. Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 65. Merck Recent Development
Table 66. Pfizer Company Detail
Table 67. Pfizer Business Overview
Table 68. Pfizer Nanocarrier-Based Vaccine Product
Table 69. Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. Novartis Company Detail
Table 72. Novartis Business Overview
Table 73. Novartis Nanocarrier-Based Vaccine Product
Table 74. Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Moderna Company Detail
Table 77. Moderna Business Overview
Table 78. Moderna Nanocarrier-Based Vaccine Product
Table 79. Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 80. Moderna Recent Development
Table 81. Research Programs/Design for This Report
Table 82. Key Data Information from Secondary Sources
Table 83. Key Data Information from Primary Sources
Table 1. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Adjuvants
Table 3. Key Players of Delivery Systems
Table 4. Global Nanocarrier-Based Vaccine Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Nanocarrier-Based Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Nanocarrier-Based Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Nanocarrier-Based Vaccine Market Share by Region (2018-2023)
Table 8. Global Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Nanocarrier-Based Vaccine Market Share by Region (2024-2029)
Table 10. Nanocarrier-Based Vaccine Market Trends
Table 11. Nanocarrier-Based Vaccine Market Drivers
Table 12. Nanocarrier-Based Vaccine Market Challenges
Table 13. Nanocarrier-Based Vaccine Market Restraints
Table 14. Global Nanocarrier-Based Vaccine Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Nanocarrier-Based Vaccine Market Share by Players (2018-2023)
Table 16. Global Top Nanocarrier-Based Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Table 17. Ranking of Global Top Nanocarrier-Based Vaccine Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Nanocarrier-Based Vaccine Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Nanocarrier-Based Vaccine Product Solution and Service
Table 21. Date of Enter into Nanocarrier-Based Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2018-2023)
Table 25. Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2024-2029)
Table 27. Global Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Nanocarrier-Based Vaccine Revenue Market Share by Application (2018-2023)
Table 29. Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Nanocarrier-Based Vaccine Revenue Market Share by Application (2024-2029)
Table 31. North America Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Nanocarrier-Based Vaccine Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Nanocarrier-Based Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 46. Emergent BioSolutions Company Detail
Table 47. Emergent BioSolutions Business Overview
Table 48. Emergent BioSolutions Nanocarrier-Based Vaccine Product
Table 49. Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 50. Emergent BioSolutions Recent Development
Table 51. Sanofi Company Detail
Table 52. Sanofi Business Overview
Table 53. Sanofi Nanocarrier-Based Vaccine Product
Table 54. Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 55. Sanofi Recent Development
Table 56. GlaxoSmithKline Biologicals Company Detail
Table 57. GlaxoSmithKline Biologicals Business Overview
Table 58. GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Product
Table 59. GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 60. GlaxoSmithKline Biologicals Recent Development
Table 61. Merck Company Detail
Table 62. Merck Business Overview
Table 63. Merck Nanocarrier-Based Vaccine Product
Table 64. Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 65. Merck Recent Development
Table 66. Pfizer Company Detail
Table 67. Pfizer Business Overview
Table 68. Pfizer Nanocarrier-Based Vaccine Product
Table 69. Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. Novartis Company Detail
Table 72. Novartis Business Overview
Table 73. Novartis Nanocarrier-Based Vaccine Product
Table 74. Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Moderna Company Detail
Table 77. Moderna Business Overview
Table 78. Moderna Nanocarrier-Based Vaccine Product
Table 79. Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 80. Moderna Recent Development
Table 81. Research Programs/Design for This Report
Table 82. Key Data Information from Secondary Sources
Table 83. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Nanocarrier-Based Vaccine Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Nanocarrier-Based Vaccine Market Share by Type: 2022 VS 2029
Figure 3. Adjuvants Features
Figure 4. Delivery Systems Features
Figure 5. Global Nanocarrier-Based Vaccine Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Nanocarrier-Based Vaccine Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Nanocarrier-Based Vaccine Report Years Considered
Figure 11. Global Nanocarrier-Based Vaccine Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Nanocarrier-Based Vaccine Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Nanocarrier-Based Vaccine Market Share by Region: 2022 VS 2029
Figure 14. Global Nanocarrier-Based Vaccine Market Share by Players in 2022
Figure 15. Global Top Nanocarrier-Based Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Nanocarrier-Based Vaccine Revenue in 2022
Figure 17. North America Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 19. United States Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 23. Germany Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Nanocarrier-Based Vaccine Market Share by Region (2018-2029)
Figure 31. China Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 39. Mexico Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 43. Turkey Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Emergent BioSolutions Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 46. Sanofi Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 47. GlaxoSmithKline Biologicals Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 48. Merck Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 49. Pfizer Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 50. Novartis Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 51. Moderna Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
Figure 1. Global Nanocarrier-Based Vaccine Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Nanocarrier-Based Vaccine Market Share by Type: 2022 VS 2029
Figure 3. Adjuvants Features
Figure 4. Delivery Systems Features
Figure 5. Global Nanocarrier-Based Vaccine Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Nanocarrier-Based Vaccine Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Nanocarrier-Based Vaccine Report Years Considered
Figure 11. Global Nanocarrier-Based Vaccine Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Nanocarrier-Based Vaccine Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Nanocarrier-Based Vaccine Market Share by Region: 2022 VS 2029
Figure 14. Global Nanocarrier-Based Vaccine Market Share by Players in 2022
Figure 15. Global Top Nanocarrier-Based Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Nanocarrier-Based Vaccine Revenue in 2022
Figure 17. North America Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 19. United States Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 23. Germany Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Nanocarrier-Based Vaccine Market Share by Region (2018-2029)
Figure 31. China Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 39. Mexico Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 43. Turkey Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Emergent BioSolutions Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 46. Sanofi Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 47. GlaxoSmithKline Biologicals Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 48. Merck Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 49. Pfizer Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 50. Novartis Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 51. Moderna Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
